YK-11

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
YK-11
YK-11.svg
Clinical data
Synonyms YK11; (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C25H34O6
Molar mass 430.54 g·mol−1
3D model (JSmol)

YK-11 is a synthetic steroidal selective androgen receptor modulator (SARM).[1][2] It is a gene-selective partial agonist of the androgen receptor (AR) and does not induce the physical interaction between the NTD/AF1 and LBD/AF2 (known as the N/C interaction), which is required for full transactivation of the AR.[1][2] The drug has anabolic activity in vitro in C2C12 myoblasts and shows greater potency than dihydrotestosterone (DHT) in this regard.[2]

See also[edit]

References[edit]

  1. ^ a b Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, Yamaguchi A, Tominaga N, Kohra S, Arizono K, Inouye Y (2011). "(17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor". Biological & Pharmaceutical Bulletin. 34 (3): 318–23. PMID 21372378. 
  2. ^ a b c Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y (2013). "Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression". Biological & Pharmaceutical Bulletin. 36 (9): 1460–5. PMID 23995658.